Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660645 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL4661948 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3898983 | 0.84 | L3MBTL1 (0.50) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064041 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064029 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064309 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13198959 | 0.84 | CA1 (0.42) | SMN1; SMN2CA1CA2BIRC2CA12 | |
| SCHEMBL3241409 | 0.83 | TAS1R3 (0.46) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL711890 | 0.83 | TAS1R3 (0.46) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13993116 | 0.82 | CA1 (0.41) | SMN1; SMN2CA1CA2BIRC2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969620-B2 | Process for the preparation of amino acid derivatives | UCB PHARMA GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20130190533-A1 | PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB PHARMA GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| WO-2011146974-A1 | METHODS FOR THE SYNTHESIS OF ALKYNE-CONTAINING DICARBA BRIDGES IN PEPTIDES | MONASH UNIVERSITY (AU) | 2011-12-01 | — | — | WO | disclosed |
| EP-1279660-B1 | Process for producing an optically active amide from an alpha, beta-unsaturated amide derivative in the presence of an optically active transition metal complex containing a phosphine-phosphorane compound and rhodium | TAKASAGO PERFUMERY CO LTD (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-6855847-B2 | Process for producing optically active amide from α β- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030120067-A1 | Process for producing optically active amide from alpha beta- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1279660-A1 | Process for producing an optically active amide from an alpha, beta-unsaturated amide derivative in the presence of a transition metal complex containing a phosphine-phosphorane compound and a transition metal | Takasago International Corporation (JP) | 2003-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190533-A1 | PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | BCAT2, BCAT1, HNMT | SMN1; SMN2 1255/4885KDM4E 1214/4885MAPT 1547/4885 |
| US-20030120067-A1 | Process for producing optically active amide from alpha beta- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | PHOSPHO1, NAAA, DEGS1 | SMN1; SMN2 2984/4885KDM4E 4438/4885MAPT 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.